is gsk undervalued:GSK (NYSE:GSK)

GSK (NYSE:GSK)

GSK (NYSE:GSK)

IsGSKundervaluedcomparedtoitsfairvalue,analystforecastsanditspricerelativetothemarket?ValuationScore.5/6 ...。其他文章還包含有:「3reasonswhyGSK'ssharepriceisabrilliantbargain!」、「AWide」、「GSK(LSE:GSK)」、「GSK(LSE」、「GSKorTECH」、「GSKPLCADRStockPriceQuote」、「GSK」、「IsGSKaStrongBuyRightNow?」

查看更多 離開網站

Provide From Google
3 reasons why GSK's share price is a brilliant bargain!
3 reasons why GSK's share price is a brilliant bargain!

https://www.fool.co.uk

Today GSK shares trade on a forward price-to-earnings growth (PEG) ratio of 0.5. Any reading below one shows that a stock is undervalued.

Provide From Google
A Wide
A Wide

https://www.morningstar.com

The undervalued wide-moat stock is among our 10 best companies to invest in now. GSK is also one of Morningstar chief U.S. market strategist ...

Provide From Google
GSK (LSE:GSK)
GSK (LSE:GSK)

https://simplywall.st

Significantly Below Fair Value: GSK is trading below fair value by more than 20%. Analyst Price Targets. What ...

Provide From Google
GSK (LSE
GSK (LSE

https://simplywall.st

Significantly Below Fair Value: GSK is trading below fair value by more than 20%. Analyst Price Targets. What is the analyst 12-month forecast and do ...

Provide From Google
GSK or TECH
GSK or TECH

https://finance.yahoo.com

GSK and Techne are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), ... whether a company is undervalued at its current share price levels.

Provide From Google
GSK PLC ADR Stock Price Quote
GSK PLC ADR Stock Price Quote

https://www.morningstar.com

We continue to view the stock as undervalued, with the market not fully appreciating the growth potential of the firm's key innovative products that also ...

Provide From Google
GSK
GSK

https://seekingalpha.com

GSK is a rare undervalued stock in the frothy pharmaceutical sector. It's demonstrating strong operating performance and expects record ...

Provide From Google
Is GSK a Strong Buy Right Now?
Is GSK a Strong Buy Right Now?

https://www.fool.com

Speaking of valuation, GSK stands out as a relatively cheap big pharma equity. With an earnings yield of 7.64%, GSK's shares are undervalued ...